Entecavir-induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide.

I Vern LimNurgül Özgür YurttaşMesut AyerŞule PoturoğluErdem Kınacıİlgin Özden

Published in: Clinical case reports (2023)

At 22 weeks post-transplantation for HBV-related cirrhosis, an adult woman developed neutropenia which was aggravated by COVID-19 (ANC 0.4 × 10 9 /L). Covid resolution and all "conventional" modifications were ineffective. Success within 2 weeks was achieved by switching entecavir to tenofovir alafenamide. A step-by-step judicious approach to post-transplant neutropenia is vital.

Keyphrases

coronavirus disease
sars cov
chemotherapy induced
hepatitis b virus
antiretroviral therapy
gestational age
high glucose
diabetic rats
respiratory syndrome coronavirus
drug induced
stem cells
cell therapy
liver failure
oxidative stress
single molecule
endothelial cells
mesenchymal stem cells
stress induced